Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Public ClinicalTrials.gov record NCT02393248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
Study identification
- NCT ID
- NCT02393248
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 201 participants
Conditions and interventions
Conditions
Interventions
- Pemigatinib Drug
- Gemcitabine Drug
- Pembrolizumab Drug
- Docetaxel Drug
- Trastuzumab Drug
- Retifanlimab Drug
- Cisplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2015
- Primary completion
- Dec 16, 2021
- Completion
- Dec 16, 2021
- Last update posted
- Jan 5, 2023
2015 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama At Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35205 | — |
| Cedars-Sinai Medical Center | West Hollywood | California | 90048 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Hematology Oncology Associates of the Tr | Port Saint Lucie | Florida | 34952 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| John Theurer Cancer Center, Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Northwell Health - Monter Cancer Center | New Hyde Park | New York | 11042 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Ohio State University - Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Signal Point Clinical Research Center | Middletown | Ohio | 45042 | — |
| Greenville Health System Cancer Institute | Greenville | South Carolina | 29605 | — |
| Mary Crowley Cancer Research Ctr | Dallas | Texas | 75230 | — |
| Md Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
| Baylor Scott & White Health | Temple | Texas | 76508 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02393248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02393248 live on ClinicalTrials.gov.